Health · Pharma & Biotech · 1 day ago
GLP-1 Care Shifts From Drug Shortages to Choice and Follow-Up
After shortages eased, semaglutide and tirzepatide became more regularly available in the US.
Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GLP-1 and GIP receptors, so they are different treatment options.
Both can cause side effects such as nausea and constipation, and providers often increase doses gradually to help patients tolerate treatment.
Choosing between treatments requires a clinical assessment that considers a person’s health, past treatment and coverage.
Research cited in the story found that some online platforms prescribed GLP-1 drugs after little interaction with a clinician, raising questions about care quality.
Ongoing follow-up matters because obesity treatment can last for years and patients may need dose changes or help managing side effects.
The next challenge is ensuring patients receive support after a prescription, not just access to medication.
The U.S. GLP-1 market has shifted from widespread shortages to broader availability and more treatment choices.
Tirzepatide and semaglutide are now regularly available, according to Digital Trends.
The article says choosing a treatment requires individual clinical evaluation, including consideration of a patient’s health, treatment history and coverage.
It also emphasizes follow-up care for dose changes, side effects and changes in a patient’s health.
Mochi Health is described as a platform that offers structured care pathways and continued access to a physician care team.
- Who
- U.S. patients, clinicians and care platforms involved in GLP-1 treatment.
- What
- The focus of GLP-1 care is shifting from drug shortages to treatment choice, quality of clinical assessment and follow-up.
- When
- The article was published on October 23, 2026. It describes supply constraints during much of 2023 and 2024.
- Where
- The United States.
- Why
- Wider availability has raised questions about how providers should select treatments and support patients over time.
This story does not have two clearly opposing sides.
Patients and clinicians navigated constrained supplies of GLP-1 medicines.
Tirzepatide came off the FDA shortage list.
Semaglutide came off the FDA shortage list.
Digital Trends published an article describing a shift toward treatment choice, access and follow-up.
- Tirzepatide shortage-list status
- Removed in December 2024
- Semaglutide shortage-list status
- Removed in February 2025
- Semaglutide mechanism
- Acts through the GLP-1 receptor
- Tirzepatide mechanism
- Acts through the GLP-1 and GIP receptors
- Article publication date
- October 23, 2026